SGLT2阻害剤市場規模、成長と動向分析レポート 2025-2033年

SGLT2阻害剤市場 – 医薬品（ジャディアンス、フォシーガ、インペファ、インヴォカナ）、適応症別（2型糖尿病、心血管）、流通チャネル別、地域、セグメント別予測による市場規模、成長と動向分析レポート 2025-2033年

世界のSGLT2阻害剤市場規模は2024年に168億米ドルと推定され、2033年には289億米ドルに達すると予測されており、2025年から2033年にかけて6.19%のCAGRで成長します。2型糖尿病および合併症に使用されるこれらの薬剤は、血糖コントロールと心血管リスクの軽減に有効であるため、需要が高まっています。

2型糖尿病の世界的な罹患率増加に加え、心血管疾患や慢性腎臓病などの関連合併症の増加により、市場は大幅な成長を遂げています。国際糖尿病連合（IDF）によると、2024年時点で世界中で約5億8,900万人の成人が糖尿病を患っており、この数字は2050年までに8億5,300万人に増加すると予想されています。糖尿病の負担増大により、医療制度はより効果的な治療選択肢を模索しており、血糖コントロールと心血管保護という二重のメリットを持つSGLT2阻害薬の人気が高まっています。エンパグリフロジンやダパグリフロジンなどのこれらの薬剤は、糖尿病患者の心血管疾患による死亡率と心不全による入院を有意に低減する効果を示しています。さらに、慢性腎臓病の治療におけるSGLT2阻害剤の役割に対する認識が高まっていることが市場の需要をさらに押し上げており、FDAが非糖尿病患者の慢性腎臓病に対するダパグリフロジンを承認したことで、2020年にはその適応症が著しく拡大しました。

SGLT2 Inhibitors Market Summary

The global SGLT2 inhibitors market size was estimated at USD 16.8 billion in 2024 and is projected to reach USD 28.9 billion by 2033, growing at a CAGR of 6.19% from 2025 to 2033. These drugs, used for Type 2 diabetes and comorbidities, are in high demand due to their effectiveness in glycemic control and cardiovascular risk reduction.

The market is experiencing significant growth due to the increasing global prevalence of Type 2 diabetes, along with related comorbidities such as cardiovascular diseases and chronic kidney disease. According to the International Diabetes Federation (IDF), nearly 589 million adults worldwide were living with diabetes in 2024, a figure that is expected to rise to 853 million by 2050. This growing burden of diabetes is prompting healthcare systems to seek more effective treatment options, with SGLT2 inhibitors gaining popularity due to their dual benefits of glycemic control and cardiovascular protection. These drugs, such as empagliflozin and dapagliflozin, have shown significant efficacy in reducing cardiovascular mortality and hospitalizations for heart failure in diabetic patients. Furthermore, the increasing recognition of the role of SGLT2 inhibitors in treating chronic kidney disease is driving further market demand, with the FDA’s approval of dapagliflozin for chronic kidney disease in non-diabetic patients marking a notable expansion of its indications in 2020.

SGLT2 Inhibitors Market Report Scope

Global SGLT2 Inhibitors Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global SGLT2 Inhibitors market report based on drug, indication, distribution channel,and region:

• Drug Outlook (Revenue, USD Million, 2021 – 2033)
• Jardiance (empagliflozin)
• Farxiga (dapagliflozin)
• Invokana (canagliflozin)
• Inpefa (sotagliflozin)
• Qtern (dapagliflozin/saxagliptin)
• Other SGLT2 Inhibitors
• Indication Outlook (Revenue, USD Million, 2021 – 2033)
• Type 2 Diabetes
• Cardiovascular
• Chronic Kidney Disease (CKD)
• Others
• Distribution Channel Outlook (Revenue, USD Million, 2021 – 2033)
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Regional Outlook (Revenue, USD Million, 2021 – 2033)
• North America

o U.S.

o Canada

o Mexico

• Europe

o Germany

o UK

o France

o Italy

o Spain

o Denmark

o Sweden

o Norway

• Asia Pacific

o China

o Japan

o India

o South Korea

o Australia

o Thailand

• Latin America

o Brazil

o Argentina

• Middle East and Africa (MEA)

o South Africa

o Saudi Arabia

o Kuwait

o UAE

Table of Contents

Chapter 1. Methodology and Scope

1.1. Market Segmentation & Scope

1.2. Segment Definitions

1.2.1. Drug

1.2.2. Indication

1.2.3. Distribution Channel

1.2.4. Regional scope

1.2.5. Estimates and forecasts timeline

1.3. Research Methodology

1.4. Information Procurement

1.4.1. Purchased database

1.4.2. GVR’s internal database

1.4.3. Secondary sources

1.4.4. Primary research

1.4.5. Details of primary research

1.4.5.1. Data for primary interviews in North America

1.4.5.2. Data for primary interviews in Europe

1.4.5.3. Data for primary interviews in Asia Pacific

1.4.5.4. Data for primary interviews in Latin America

1.4.5.5. Data for Primary interviews in MEA

1.5. Information or Data Analysis

1.5.1. Data analysis models

1.6. Market Formulation & Validation

1.7. Model Details

1.7.1. Commodity flow analysis (Model 1)

1.7.2. Approach 1: Commodity flow approach

1.7.3. Volume price analysis (Model 2)

1.7.4. Approach 2: Volume price analysis

1.8. List of Secondary Sources

1.9. List of Primary Sources

1.10. Objectives

Chapter 2. Executive Summary

2.1. Market Outlook

2.2. Segment Outlook

2.2.1. Drug and Indication outlook

2.2.2. Distribution Channel outlook

2.2.3. Regional outlook

2.3. Competitive Insights

Chapter 3. SGLT2 Inhibitors Market Variables, Trends & Scope

3.1. Market Lineage Outlook

3.1.1. Parent market outlook

3.1.2. Related/ancillary market outlook

3.2. Market Dynamics

3.2.1. Market driver analysis

3.2.1.1. Increasing prevalence of target disease

3.2.1.2. Technological advancements in drug development

3.2.1.3. Growing awareness and diagnosis

3.2.2. Market restraint analysis

3.2.2.1. High cost of drug development

3.2.2.2. Stringent regulatory policies for drug approval

3.3. SGLT2 Inhibitors Market Analysis Tools

3.3.1. Industry Analysis – Porter’s

3.3.1.1. Supplier power

3.3.1.2. Buyer power

3.3.1.3. Substitution threat

3.3.1.4. Threat of new entrant

3.3.1.5. Competitive rivalry

3.3.2. PESTEL Analysis

3.3.2.1. Political landscape

3.3.2.2. Technological landscape

3.3.2.3. Economic landscape

3.3.3. Pipeline Analysis

3.3.4. Target population analysis

Chapter 4. SGLT2 Inhibitors Market: Drug Estimates & Trend Analysis

4.1. Global SGLT2 Inhibitors Market: Drug Dashboard

4.2. Global SGLT2 Inhibitors Market: Drug Movement Analysis

4.3. Global SGLT2 Inhibitors Market By Drug, Revenue

4.4. Jardiance (empagliflozin)

4.4.1. Jardiance (empagliflozin) market estimates and forecasts, 2021 – 2033 (USD Million)

4.5. Farxiga (dapagliflozin)

4.5.1. Farxiga (dapagliflozin) market estimates and forecasts, 2021 – 2033 (USD Million)

4.6. Invokana (canagliflozin)

4.6.1. Invokana (canagliflozin) market estimates and forecasts, 2021 – 2033 (USD Million)

4.7. Inpefa (sotagliflozin)

4.7.1. Inpefa (sotagliflozin) market estimates and forecasts, 2021 – 2033 (USD Million)

4.8. Qtern (dapagliflozin/saxagliptin)

4.8.1. Qtern (dapagliflozin/saxagliptin) market estimates and forecasts, 2021 – 2033 (USD Million)

4.9. Other SGLT2 Inhibitors

4.9.1. Other SGLT2 inhibitors market estimates and forecasts, 2021 – 2033 (USD Million)

Chapter 5. SGLT2 Inhibitors Market: Indication Estimates & Trend Analysis

5.1. Global SGLT2 Inhibitors Market: Indication Dashboard

5.2. Global SGLT2 Inhibitors Market: Indication Movement Analysis

5.3. Global SGLT2 Inhibitors Market Estimates and Forecasts, By Indication, Revenue (USD Million)

5.4. Type 2 Diabetes

5.4.1. Type 2 diabetes market estimates and forecasts, 2021 – 2033 (USD Million)

5.5. Cardiovascular

5.5.1. Cardiovascular market estimates and forecasts, 2021 – 2033 (USD Million)

5.6. Chronic Kidney Disease (CKD)

5.6.1. Chronic kidney disease (CKD) market estimates and forecasts, 2021 – 2033 (USD Million)

5.7. Others

5.7.1. Others market estimates and forecasts, 2021 – 2033 (USD Million)

Chapter 6. SGLT2 Inhibitors Market: Distribution Channel Estimates & Trend Analysis

6.1. Global SGLT2 Inhibitors Market: Distribution Channel Dashboard

6.2. Global SGLT2 Inhibitors Market: Distribution Channel Movement Analysis

6.3. Global SGLT2 Inhibitors Market Estimates and Forecasts, by Distribution Channel, Revenue (USD Million)

6.4. Hospital Pharmacies

6.4.1. Hospital pharmacies market estimates and forecasts, 2021 – 2033 (USD Million)

6.5. Retail Pharmacies

6.5.1. Retail pharmacies market estimates and forecasts, 2021 – 2033 (USD Million)

6.6. Online Pharmacies

6.6.1. Online pharmacies market estimates and forecasts, 2021 – 2033 (USD Million)

Chapter 7. SGLT2 Inhibitors Market: Regional Estimates & Trend Analysis By Drug, Indication, and Distribution Channel

7.1. Regional Dashboard

7.2. Market Size, & Forecasts Trend Analysis, 2021 to 2033:

7.3. North America

7.3.1. U.S.

7.3.1.1. Key country dynamics

7.3.1.2. Regulatory framework/ reimbursement structure

7.3.1.3. Competitive scenario

7.3.1.4. U.S. market estimates and forecasts, 2021 – 2033 (USD Million)

7.3.2. Canada

7.3.2.1. Key country dynamics

7.3.2.2. Regulatory framework/ reimbursement structure

7.3.2.3. Competitive scenario

7.3.2.4. Canada market estimates and forecasts, 2021 – 2033 (USD Million)

7.3.3. Mexico

7.3.3.1. Key country dynamics

7.3.3.2. Regulatory framework/ reimbursement structure

7.3.3.3. Competitive scenario

7.3.3.4. Mexico market estimates and forecasts, 2021 – 2033 (USD Million)

7.4. Europe

7.4.1. UK

7.4.1.1. Key country dynamics

7.4.1.2. Regulatory framework/ reimbursement structure

7.4.1.3. Competitive scenario

7.4.1.4. UK market estimates and forecasts, 2021 – 2033 (USD Million)

7.4.2. Germany

7.4.2.1. Key country dynamics

7.4.2.2. Regulatory framework/ reimbursement structure

7.4.2.3. Competitive scenario

7.4.2.4. Germany market estimates and forecasts, 2021 – 2033 (USD Million)

7.4.3. France

7.4.3.1. Key country dynamics

7.4.3.2. Regulatory framework/ reimbursement structure

7.4.3.3. Competitive scenario

7.4.3.4. France market estimates and forecasts, 2021 – 2033 (USD Million)

7.4.4. Italy

7.4.4.1. Key country dynamics

7.4.4.2. Regulatory framework/ reimbursement structure

7.4.4.3. Competitive scenario

7.4.4.4. Italy market estimates and forecasts, 2021 – 2033 (USD Million)

7.4.5. Spain

7.4.5.1. Key country dynamics

7.4.5.2. Regulatory framework/ reimbursement structure

7.4.5.3. Competitive scenario

7.4.5.4. Spain market estimates and forecasts, 2021 – 2033 (USD Million)

7.4.6. Norway

7.4.6.1. Key country dynamics

7.4.6.2. Regulatory framework/ reimbursement structure

7.4.6.3. Competitive scenario

7.4.6.4. Norway market estimates and forecasts, 2021 – 2033 (USD Million)

7.4.7. Sweden

7.4.7.1. Key country dynamics

7.4.7.2. Regulatory framework/ reimbursement structure

7.4.7.3. Competitive scenario

7.4.7.4. Sweden market estimates and forecasts, 2021 – 2033 (USD Million)

7.4.8. Denmark

7.4.8.1. Key country dynamics

7.4.8.2. Regulatory framework/ reimbursement structure

7.4.8.3. Competitive scenario

7.4.8.4. Denmark market estimates and forecasts, 2021 – 2033 (USD Million)

7.5. Asia Pacific

7.5.1. Japan

7.5.1.1. Key country dynamics

7.5.1.2. Regulatory framework/ reimbursement structure

7.5.1.3. Competitive scenario

7.5.1.4. Japan market estimates and forecasts, 2021 – 2033 (USD Million)

7.5.2. China

7.5.2.1. Key country dynamics

7.5.2.2. Regulatory framework/ reimbursement structure

7.5.2.3. Competitive scenario

7.5.2.4. China market estimates and forecasts, 2021 – 2033 (USD Million)

7.5.3. India

7.5.3.1. Key country dynamics

7.5.3.2. Regulatory framework/ reimbursement structure

7.5.3.3. Competitive scenario

7.5.3.4. India market estimates and forecasts, 2021 – 2033 (USD Million)

7.5.4. Australia

7.5.4.1. Key country dynamics

7.5.4.2. Regulatory framework/ reimbursement structure

7.5.4.3. Competitive scenario

7.5.4.4. Australia market estimates and forecasts, 2021 – 2033 (USD Million)

7.5.5. South Korea

7.5.5.1. Key country dynamics

7.5.5.2. Regulatory framework/ reimbursement structure

7.5.5.3. Competitive scenario

7.5.5.4. South Korea market estimates and forecasts, 2021 – 2033 (USD Million)

7.5.6. Thailand

7.5.6.1. Key country dynamics

7.5.6.2. Regulatory framework/ reimbursement structure

7.5.6.3. Competitive scenario

7.5.6.4. Thailand market estimates and forecasts, 2021 – 2033 (USD Million)

7.6. Latin America

7.6.1. Brazil

7.6.1.1. Key country dynamics

7.6.1.2. Regulatory framework/ reimbursement structure

7.6.1.3. Competitive scenario

7.6.1.4. Brazil market estimates and forecasts, 2021 – 2033 (USD Million)

7.6.2. Argentina

7.6.2.1. Key country dynamics

7.6.2.2. Regulatory framework/ reimbursement structure

7.6.2.3. Competitive scenario

7.6.2.4. Argentina market estimates and forecasts, 2021 – 2033 (USD Million)

7.7. MEA

7.7.1. South Africa

7.7.1.1. Key country dynamics

7.7.1.2. Regulatory framework/ reimbursement structure

7.7.1.3. Competitive scenario

7.7.1.4. South Africa market estimates and forecasts, 2021 – 2033 (USD Million)

7.7.2. Saudi Arabia

7.7.2.1. Key country dynamics

7.7.2.2. Regulatory framework/ reimbursement structure

7.7.2.3. Competitive scenario

7.7.2.4. Saudi Arabia market estimates and forecasts, 2021 – 2033 (USD Million)

7.7.3. UAE

7.7.3.1. Key country dynamics

7.7.3.2. Regulatory framework/ reimbursement structure

7.7.3.3. Competitive scenario

7.7.3.4. UAE market estimates and forecasts, 2021 – 2033 (USD Million)

7.7.4. Kuwait

7.7.4.1. Key country dynamics

7.7.4.2. Regulatory framework/ reimbursement structure

7.7.4.3. Competitive scenario

7.7.4.4. Kuwait market estimates and forecasts, 2021 – 2033 (USD Million)

Chapter 8. Competitive Landscape

8.1. Recent Developments & Impact Analysis, By Key Market Participants

8.2. Company/Competition Categorization

8.3. Vendor Landscape

8.3.1. List of key distributors and channel partners

8.3.2. Key customers

8.3.3. Key company market share analysis, 2023

8.3.4. Boehringer Ingelheim International GmbH.

8.3.4.1. Company overview

8.3.4.2. Financial performance

8.3.4.3. Product benchmarking

8.3.4.4. Strategic initiatives

8.3.5. AstraZeneca

8.3.5.1. Company overview

8.3.5.2. Financial performance

8.3.5.3. Product benchmarking

8.3.5.4. Strategic initiatives

8.3.6. Merck & Co., Inc.

8.3.6.1. Company overview

8.3.6.2. Financial performance

8.3.6.3. Product benchmarking

8.3.6.4. Strategic initiatives

8.3.7. Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals, Inc.)

8.3.7.1. Company overview

8.3.7.2. Financial performance

8.3.7.3. Product benchmarking

8.3.7.4. Strategic initiatives

8.3.8. TheracosBio, LLC

8.3.8.1. Company overview

8.3.8.2. Financial performance

8.3.8.3. Product benchmarking

8.3.8.4. Strategic initiatives

8.3.9. Lexicon Pharmaceuticals, Inc.

8.3.9.1. Company overview

8.3.9.2. Financial performance

8.3.9.3. Product benchmarking

8.3.9.4. Strategic initiatives

8.3.10. Eli Lilly and Company

8.3.10.1. Company overview

8.3.10.2. Financial performance

8.3.10.3. Product benchmarking

8.3.10.4. Strategic initiatives

8.3.11. Bristol-Myers Squibb Company

8.3.11.1. Company overview

8.3.11.2. Financial performance

8.3.11.3. Product benchmarking

8.3.11.4. Strategic initiatives

8.3.12. Glenmark Pharmaceuticals Ltd

8.3.12.1. Company overview

8.3.12.2. Financial performance

8.3.12.3. Product benchmarking

8.3.12.4. Strategic initiatives

List of Tables

Table 1 List of abbreviation

Table 2 North America SGLT2 Inhibitors market, by region, 2021 – 2033 (USD Million)

Table 3 North America SGLT2 Inhibitors market, by drug, 2021 – 2033 (USD Million)

Table 4 North America SGLT2 Inhibitors market, by indication, 2021 – 2033 (USD Million)

Table 5 North America SGLT2 Inhibitors market, by distribution channel, 2021 – 2033 (USD Million)

Table 6 U.S. SGLT2 Inhibitors market, by drug, 2021 – 2033 (USD Million)

Table 7 U.S. SGLT2 Inhibitors market, by indication, 2021 – 2033 (USD Million)

Table 8 U.S. SGLT2 Inhibitors market, by distribution channel, 2021 – 2033 (USD Million)

Table 9 Canada SGLT2 Inhibitors market, by drug, 2021 – 2033 (USD Million)

Table 10 Canada SGLT2 Inhibitors market, by indication, 2021 – 2033 (USD Million)

Table 11 Canada SGLT2 Inhibitors market, by distribution channel, 2021 – 2033 (USD Million)

Table 12 Mexico SGLT2 Inhibitors market, by drug, 2021 – 2033 (USD Million)

Table 13 Mexico SGLT2 Inhibitors market, by indication, 2021 – 2033 (USD Million)

Table 14 Mexico SGLT2 Inhibitors market, by distribution channel, 2021 – 2033 (USD Million)

Table 15 Europe SGLT2 Inhibitors market, by region, 2021 – 2033 (USD Million)

Table 16 Europe SGLT2 Inhibitors market, by drug, 2021 – 2033 (USD Million)

Table 17 Europe SGLT2 Inhibitors market, by indication, 2021 – 2033 (USD Million)

Table 18 Europe SGLT2 Inhibitors market, by distribution channel, 2021 – 2033 (USD Million)

Table 19 Germany SGLT2 Inhibitors market, by drug, 2021 – 2033 (USD Million)

Table 20 Germany SGLT2 Inhibitors market, by indication, 2021 – 2033 (USD Million)

Table 21 Germany SGLT2 Inhibitors market, by distribution channel, 2021 – 2033 (USD Million)

Table 22 UK SGLT2 Inhibitors market, by drug, 2021 – 2033 (USD Million)

Table 23 UK SGLT2 Inhibitors market, by indication, 2021 – 2033 (USD Million)

Table 24 UK SGLT2 Inhibitors market, by distribution channel, 2021 – 2033 (USD Million)

Table 25 France SGLT2 Inhibitors market, by drug, 2021 – 2033 (USD Million)

Table 26 France SGLT2 Inhibitors market, by indication, 2021 – 2033 (USD Million)

Table 27 France SGLT2 Inhibitors market, by distribution channel, 2021 – 2033 (USD Million)

Table 28 Italy SGLT2 Inhibitors market, by drug, 2021 – 2033 (USD Million)

Table 29 Italy SGLT2 Inhibitors market, by indication, 2021 – 2033 (USD Million)

Table 30 Italy SGLT2 Inhibitors market, by distribution channel, 2021 – 2033 (USD Million)

Table 31 Spain SGLT2 Inhibitors market, by drug, 2021 – 2033 (USD Million)

Table 32 Spain SGLT2 Inhibitors market, by indication, 2021 – 2033 (USD Million)

Table 33 Spain SGLT2 Inhibitors market, by distribution channel, 2021 – 2033 (USD Million)

Table 34 Denmark SGLT2 Inhibitors market, by drug, 2021 – 2033 (USD Million)

Table 35 Denmark SGLT2 Inhibitors market, by indication, 2021 – 2033 (USD Million)

Table 36 Denmark SGLT2 Inhibitors market, by distribution channel, 2021 – 2033 (USD Million)

Table 37 Sweden SGLT2 Inhibitors market, by drug, 2021 – 2033 (USD Million)

Table 38 Sweden SGLT2 Inhibitors market, by indication, 2021 – 2033 (USD Million)

Table 39 Sweden SGLT2 Inhibitors market, by distribution channel, 2021 – 2033 (USD Million)

Table 40 Norway SGLT2 Inhibitors market, by drug, 2021 – 2033 (USD Million)

Table 41 Norway SGLT2 Inhibitors market, by indication, 2021 – 2033 (USD Million)

Table 42 Norway SGLT2 Inhibitors market, by distribution channel, 2021 – 2033 (USD Million)

Table 43 Asia Pacific SGLT2 Inhibitors market, by region, 2021 – 2033 (USD Million)

Table 44 Asia Pacific SGLT2 Inhibitors market, by drug, 2021 – 2033 (USD Million)

Table 45 Asia Pacific SGLT2 Inhibitors market, by indication, 2021 – 2033 (USD Million)

Table 46 Aisa Pacific SGLT2 Inhibitors market, by distribution channel, 2021 – 2033 (USD Million)

Table 47 China SGLT2 Inhibitors market, by drug, 2021 – 2033 (USD Million)

Table 48 China SGLT2 Inhibitors market, by indication, 2021 – 2033 (USD Million)

Table 49 China SGLT2 Inhibitors market, by distribution channel, 2021 – 2033 (USD Million)

Table 50 Japan SGLT2 Inhibitors market, by drug, 2021 – 2033 (USD Million)

Table 51 Japan SGLT2 Inhibitors market, by indication, 2021 – 2033 (USD Million)

Table 52 Japan SGLT2 Inhibitors market, by distribution channel, 2021 – 2033 (USD Million)

Table 53 India SGLT2 Inhibitors market, by drug, 2021 – 2033 (USD Million)

Table 54 India SGLT2 Inhibitors market, by indication, 2021 – 2033 (USD Million)

Table 55 India SGLT2 Inhibitors market, by distribution channel, 2021 – 2033 (USD Million)

Table 56 South Korea SGLT2 Inhibitors market, by drug, 2021 – 2033 (USD Million)

Table 57 South Korea SGLT2 Inhibitors market, by indication, 2021 – 2033 (USD Million)

Table 58 South Korea SGLT2 Inhibitors market, by distribution channel, 2021 – 2033 (USD Million)

Table 59 Australia SGLT2 Inhibitors market, by drug, 2021 – 2033 (USD Million)

Table 60 Australia SGLT2 Inhibitors market, by indication, 2021 – 2033 (USD Million)

Table 61 Australia SGLT2 Inhibitors market, by distribution channel, 2021 – 2033 (USD Million)

Table 62 Thailand SGLT2 Inhibitors market, by drug, 2021 – 2033 (USD Million)

Table 63 Thailand SGLT2 Inhibitors market, by indication, 2021 – 2033 (USD Million)

Table 64 Thailand SGLT2 Inhibitors market, by distribution channel, 2021 – 2033 (USD Million)

Table 65 Latin America SGLT2 Inhibitors market, by region, 2021 – 2033 (USD Million)

Table 66 Latin America SGLT2 Inhibitors market, by drug, 2021 – 2033 (USD Million)

Table 67 Latin America SGLT2 Inhibitors market, by indication, 2021 – 2033 (USD Million)

Table 68 Latin America SGLT2 Inhibitors market, by distribution channel, 2021 – 2033 (USD Million)

Table 69 Brazil SGLT2 Inhibitors market, by drug, 2021 – 2033 (USD Million)

Table 70 Brazil SGLT2 Inhibitors market, by indication, 2021 – 2033 (USD Million)

Table 71 Brazil SGLT2 Inhibitors market, by distribution channel, 2021 – 2033 (USD Million)

Table 72 Argentina SGLT2 Inhibitors market, by drug, 2021 – 2033 (USD Million)

Table 73 Argentina SGLT2 Inhibitors market, by indication, 2021 – 2033 (USD Million)

Table 74 Argentina SGLT2 Inhibitors market, by distribution channel, 2021 – 2033 (USD Million)

Table 75 MEA SGLT2 Inhibitors market, by region, 2021 – 2033 (USD Million)

Table 76 MEA SGLT2 Inhibitors market, by drug, 2021 – 2033 (USD Million)

Table 77 MEA SGLT2 Inhibitors market, by indication, 2021 – 2033 (USD Million)

Table 78 MEA SGLT2 Inhibitors market, by distribution channel, 2021 – 2033 (USD Million)

Table 79 South Africa SGLT2 Inhibitors market, by drug, 2021 – 2033 (USD Million)

Table 80 South Africa SGLT2 Inhibitors market, by indication, 2021 – 2033 (USD Million)

Table 81 South Africa SGLT2 Inhibitors market, by distribution channel, 2021 – 2033 (USD Million)

Table 82 Saudi Arabia SGLT2 Inhibitors market, by drug, 2021 – 2033 (USD Million)

Table 83 Saudi Arabia SGLT2 Inhibitors market, by indication, 2021 – 2033 (USD Million)

Table 84 Saudi Arabia SGLT2 Inhibitors market, by distribution channel, 2021 – 2033 (USD Million)

Table 85 UAE SGLT2 Inhibitors market, by drug, 2021 – 2033 (USD Million)

Table 86 UAE SGLT2 Inhibitors market, by indication, 2021 – 2033 (USD Million)

Table 87 UAE SGLT2 Inhibitors market, by distribution channel, 2021 – 2033 (USD Million)

Table 88 Kuwait SGLT2 Inhibitors market, by drug, 2021 – 2033 (USD Million)

Table 89 Kuwait SGLT2 Inhibitors market, by indication, 2021 – 2033 (USD Million)

Table 90 Kuwait SGLT2 Inhibitors market, by distribution channel, 2021 – 2033 (USD Million)

List of Figures

Fig. 1 Market research process

Fig. 2 Data triangulation techniques

Fig. 3 Primary research pattern

Fig. 4 Primary interviews in North America

Fig. 5 Primary interviews in Europe

Fig. 6 Primary interviews in APAC

Fig. 7 Primary interviews in Latin America

Fig. 8 Primary interviews in MEA

Fig. 9 Market research approaches

Fig. 10 Value-chain-based sizing & forecasting

Fig. 11 QFD modeling for market share assessment

Fig. 12 Market formulation & validation

Fig. 13 SGLT2 Inhibitors market: market outlook

Fig. 14 SGLT2 Inhibitors competitive insights

Fig. 15 Parent market outlook

Fig. 16 Related/ancillary market outlook

Fig. 17 SGLT2 Inhibitors market driver impact

Fig. 18 SGLT2 Inhibitors market restraint impact

Fig. 19 SGLT2 Inhibitors market: Drug movement analysis

Fig. 20 SGLT2 Inhibitors market: Drug outlook and key takeaways

Fig. 21 Jardiance (empagliflozin) market estimates and forecast, 2021 – 2033 (USD Million)

Fig. 22 Farxiga (dapagliflozin) estimates and forecast, 2021 – 2033 (USD Million)

Fig. 23 Steglatro (ertugliflozin) market estimates and forecast, 2021 – 2033 (USD Million)

Fig. 24 Invokana (canagliflozin) estimates and forecast, 2021 – 2033 (USD Million)

Fig. 25 Brenzavvy (bexagliflozin) estimates and forecast, 2021 – 2033 (USD Million)

Fig. 26 Inpefa (sotagliflozin) estimates and forecast, 2021 – 2033 (USD Million)

Fig. 27 Other SGLT2 inhibitors estimates and forecast, 2021 – 2033 (USD Million)

Fig. 28 SGLT2 Inhibitors market: Indication movement analysis

Fig. 29 SGLT2 Inhibitors market: Indication outlook and key takeaways

Fig. 30 Type 2 diabetes market estimates and forecast, 2021 – 2033 (USD Million)

Fig. 31 Cardiovascular market estimates and forecast, 2021 – 2033 (USD Million)

Fig. 32 Chronic kidney disease (CKD) market estimates and forecast, 2021 – 2033 (USD Million)

Fig. 33 Others market estimates and forecast, 2021 – 2033 (USD Million)

Fig. 34 SGLT2 Inhibitors market: Distribution channel movement analysis

Fig. 35 SGLT2 Inhibitors market: Distribution channel outlook and key takeaways

Fig. 36 Hospital pharmacies market estimates and forecast, 2021 – 2033 (USD Million)

Fig. 37 Retail pharmacies market estimates and forecast, 2021 – 2033 (USD Million)

Fig. 38 Online pharmacies market estimates and forecast, 2021 – 2033 (USD Million)

Fig. 39 Global SGLT2 Inhibitors market: Regional movement analysis

Fig. 40 Global SGLT2 Inhibitors market: Regional outlook and key takeaways

Fig. 41 Global SGLT2 Inhibitors market share and leading players

Fig. 42 North America, by country

Fig. 43 North America market estimates and forecasts, 2021 – 2033 (USD Million)

Fig. 44 U.S. key country dynamics

Fig. 45 U.S. market estimates and forecasts, 2021 – 2033 (USD Million)

Fig. 46 Canada key country dynamics

Fig. 47 Canada market estimates and forecasts, 2021 – 2033 (USD Million)

Fig. 48 Mexico key country dynamics

Fig. 49 Mexico market estimates and forecasts, 2021 – 2033 (USD Million)

Fig. 50 Europe market estimates and forecasts, 2021 – 2033 (USD Million)

Fig. 51 UK key country dynamics

Fig. 52 UK market estimates and forecasts, 2021 – 2033 (USD Million)

Fig. 53 Germany key country dynamics

Fig. 54 Germany market estimates and forecasts, 2021 – 2033 (USD Million)

Fig. 55 France key country dynamics

Fig. 56 France market estimates and forecasts, 2021 – 2033 (USD Million)

Fig. 57 Italy key country dynamics

Fig. 58 Italy market estimates and forecasts, 2021 – 2033 (USD Million)

Fig. 59 Spain key country dynamics

Fig. 60 Spain market estimates and forecasts, 2021 – 2033 (USD Million)

Fig. 61 Denmark key country dynamics

Fig. 62 Denmark market estimates and forecasts, 2021 – 2033 (USD Million)

Fig. 63 Sweden key country dynamics

Fig. 64 Sweden market estimates and forecasts, 2021 – 2033 (USD Million)

Fig. 65 Norway key country dynamics

Fig. 66 Norway market estimates and forecasts, 2021 – 2033 (USD Million)

Fig. 67 Asia Pacific market estimates and forecasts, 2021 – 2033 (USD Million)

Fig. 68 China key country dynamics

Fig. 69 China market estimates and forecasts, 2021 – 2033 (USD Million)

Fig. 70 Japan key country dynamics

Fig. 71 Japan market estimates and forecasts, 2021 – 2033 (USD Million)

Fig. 72 India key country dynamics

Fig. 73 India market estimates and forecasts, 2021 – 2033 (USD Million)

Fig. 74 Thailand key country dynamics

Fig. 75 Thailand market estimates and forecasts, 2021 – 2033 (USD Million)

Fig. 76 South Korea key country dynamics

Fig. 77 South Korea market estimates and forecasts, 2021 – 2033 (USD Million)

Fig. 78 Australia key country dynamics

Fig. 79 Australia market estimates and forecasts, 2021 – 2033 (USD Million)

Fig. 80 Latin America market estimates and forecasts, 2021 – 2033 (USD Million)

Fig. 81 Brazil key country dynamics

Fig. 82 Brazil market estimates and forecasts, 2021 – 2033 (USD Million)

Fig. 83 Argentina key country dynamics

Fig. 84 Argentina market estimates and forecasts, 2021 – 2033 (USD Million)

Fig. 85 Middle East and Africa market estimates and forecasts, 2021 – 2033 (USD Million)

Fig. 86 South Africa key country dynamics

Fig. 87 South Africa market estimates and forecasts, 2021 – 2033 (USD Million)

Fig. 88 Saudi Arabia key country dynamics

Fig. 89 Saudi Arabia market estimates and forecasts, 2021 – 2033 (USD Million)

Fig. 90 UAE key country dynamics

Fig. 91 UAE market estimates and forecasts, 2021 – 2033 (USD Million)

Fig. 92 Kuwait key country dynamics

Fig. 93 Kuwait market estimates and forecasts, 2021 – 2033 (USD Million)

Fig. 94 Market share of key market players – SGLT2 Inhibitors market

Grand View Researchについて

Grand View Research（グランドビューリサーチ） はインドと米国を拠点とする市場調査およびコンサルティング会社です。世界中主要 25ヵ国・ 46 業界に関する豊富なデータベースを活用した市場情報は世界の企業団体に活用・引用されています。日本からのレポートのご注文・ご購入相談はお気軽にお問い合わせください。

ライセンス別価格表

調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。

ライセンスタイプ 1

ライセンスタイプ 2

ライセンスタイプ 3

ライセンスタイプ 4

ご購入に関するご案内

価格・納期について

• 価格
  • ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
• ライセンス
  • シングルユーザライセンス（インディビジュアルライセンス）
    • 1名のみレポートファイル（印刷不可）をご利用いただけます。
  • チームライセンス
    • 同一企業（関連会社除く）内5名まで共有可能です。印刷可能な電子ファイルをご提供いたします。
  • コーポレートライセンス
    • 同一企業および関連会社内で人数無制限で共有可能です。印刷可能な電子ファイルをご提供いたします。
    • 「関連会社」の範囲についてはお気軽にお問い合わせください。
• 納品形態
  • オンラインダウンロード
• 納期
  • ご注文後1～7営業日　※レポートにより異なります。

ご注文方法

• レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。

その他

• 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。

最新出版レポート

• イーサネット測定機器市場規模、成長と動向分析レポート 2025-2033年
• AIビデオ分析市場規模、成長と動向分析レポート 2025-2033年
• イベントマネジメント市場規模、成長と動向分析レポート 2025-2033年
• IPTVソフトウェア市場規模、成長と動向分析レポート 2025-2033年
• スマートホームセキュリティカメラ市場規模、成長と動向分析レポート 2025-2033年

出版レポート一覧